These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 31207601)

  • 21. Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene.
    Horiike N; Michitaka K; Masumoto T; Okura I; Akbar SM; Onji M
    J Gastroenterol Hepatol; 1999 Apr; 14(4):345-51. PubMed ID: 10207784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections.
    Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM
    Infect Genet Evol; 2019 Apr; 69():76-84. PubMed ID: 30654177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of hepatitis C virus type and subtype distribution in Hungary].
    Gervain J
    Orv Hetil; 2018 May; 159(Suppl 2):2-8. PubMed ID: 29847988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.
    Hino K; Yamaguchi Y; Fujiwara D; Katoh Y; Korenaga M; Okazaki M; Okuda M; Okita K
    J Viral Hepat; 2000 Jan; 7(1):36-42. PubMed ID: 10718941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
    J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
    Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease.
    Sartori M; Andorno S; Avogadro E; Ballarè M; La Terra G; Leone F; Quaglia V; Fortina G; Aglietta M
    Ital J Gastroenterol; 1996; 28(8):452-6. PubMed ID: 9032588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
    Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
    World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.